Ensign Peak Advisors
BMRN icon

Ensign Peak Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ensign Peak Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
9,718
+300
+3% +$16.4K ﹤0.01% 952
2026
Q1 		$532K Hold
9,418
– – ﹤0.01% 948
2025
Q4 		$560K Sell
9,418
-19,250
-67% -$1.05M ﹤0.01% 931
2025
Q3 		$1.55M Sell
28,668
-30,350
-51% -$1.74M ﹤0.01% 878
2025
Q2 		$3.24M Sell
59,018
-3,348
-5% -$197K 0.01% 742
2025
Q1 		$4.41M Buy
62,366
+498
+0.8% +$33.5K 0.01% 665
2024
Q4 		$4.07M Sell
61,868
-5,995
-9% -$402K 0.01% 699
2024
Q3 		$4.77M Sell
67,863
-4,025
-6% -$336K 0.01% 638
2024
Q2 		$5.92M Sell
71,888
-280
-0.4% -$23.3K 0.01% 581
2024
Q1 		$6.3M Sell
72,168
-85,808
-54% -$7.68M 0.01% 566
2023
Q4 		$15.2M Buy
157,976
+38,095
+32% +$3.37M 0.03% 342
2023
Q3 		$10.6M Sell
119,881
-2,070
-2% -$184K 0.02% 376
2023
Q2 		$10.6M Buy
121,951
+16,252
+15% +$1.53M 0.02% 404
2023
Q1 		$10.3M Sell
105,699
-136,402
-56% -$14.1M 0.02% 406
2022
Q4 		$25.1M Buy
242,101
+22,529
+10% +$2.11M 0.06% 260
2022
Q3 		$18.6M Buy
219,572
+129,246
+143% +$11.5M 0.05% 283
2022
Q2 		$7.49M Buy
90,326
+44,936
+99% +$3.58M 0.02% 427
2022
Q1 		$3.5M Sell
45,390
-7,800
-15% -$653K 0.01% 688
2021
Q4 		$4.7M Buy
+53,190
New +$4.39M 0.01% 682
2020
Q4 		– Sell
-16,459
Closed -$1.25M – 1858
2020
Q3 		$1.25M Buy
+16,459
New +$1.67M ﹤0.01% 1207
2020
Q1 		– Sell
-10,550
Closed -$892K – 1630
2019
Q4 		$892K Buy
+10,550
New +$797K ﹤0.01% 1372

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ensign Peak Advisors's BMRN Position: Q2 2026 in Review

Ensign Peak Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 3.2% in Q2 2026, buying an estimated $16.4K and bringing the position to 9,718 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #952.

Ensign Peak Advisors first reported a position in BMRN in Q4 2019 and has held it in 21 quarters since. The position peaked at $25.1M in Q4 2022. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Ensign Peak Advisors held 9,718 shares of BioMarin Pharmaceuticals worth $556K as of Q2 2026.
  • Ensign Peak Advisors bought 300 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $16.4K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #952 holding.
  • Ensign Peak Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Ensign Peak Advisors's BioMarin Pharmaceuticals position peaked at $25.1M in Q4 2022.
  • 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.